HFA Premium Access

Persistence to guideline-based therapy newly prescribed after a hospitalization for heart failure. Data from two large cohorts in the US and Germany.

Congress Presentation

About the speaker

Doctor Alexander Michel

Bayer AG, Basel (Switzerland)
0 follower

7 more presentations in this session

Benefits of empagliflozin in Hispanics and non-Hispanics with heart failure: a sub-analysis of the EMPEROR-trials

Speaker: Doctor M. Gamero (Philadelphia, US)


Real world data comparing HF guideline directed medical therapy before and after 2021 ESC HF guidelines.

Speaker: Mr M. Ferrari (Brescia, IT)


Prognostic impact of pharmacotherapy optimisation status in HFrEF patients using a contemporary measurement score

Speaker: Doctor A. Jordan (Mexico City, MX)


Beta-blockers and antiplatelet therapy in Takotsubo syndrome - To do or not to do?

Speaker: Doctor P. Rocha Carvalho (Vila Real, PT)


Hydrochlorothiazide for the treatment of acute volume overload worsening heart failure

Speaker: Associate Professor R. Rascon Sabido (Veracruz, MX)


Access the full session

Chronic heart failure - pharmacotherapy 3

Speakers: Doctor A. Michel, Doctor M. Gamero, Mr M. Ferrari, Doctor A. Jordan, Doctor P. Rocha Carvalho...

About the event


Heart Failure 2023

20 May - 23 May 2023

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb